Treatment planning for dose escalation in non-small cell lung cancer (NSCLC)

Medical Dosimetry

Volumn 29, Issue 3, 2004, Pages 196-203

  Schild, Steven E ^a   Korte, Shawn M ^a   Wong, William W ^a   Vora, Sujay A ^a   Younggren, James A ^a   Ezzell, Gary A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Dose escalation; Lung cancer; Prophylactic nodal irradiation; Radiotherapy treatment planning

Indexed keywords

ARTICLE; CANCER CENTER; CANCER RADIOTHERAPY; CLINICAL EXAMINATION; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED STUDY; DOSIMETRY; DRUG MEGADOSE; DYNAMICS; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LUNG NON SMALL CELL CANCER; PATIENT SELECTION; PRIORITY JOURNAL; RADIATION BEAM; RADIATION FIELD; RADIATION MONITORING; ROTATION; TREATMENT PLANNING; WEIGHT; X RAY;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; RADIATION INJURIES; RADIOGRAPHY, INTERVENTIONAL; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; SOFTWARE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 8444240386     PISSN: 09583947     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.meddos.2004.03.017     Document Type: Article

References (22)

1. Jemal A., Thomas A., Murray T., et al. Cancer statistics 2002. CA Cancer J. Clin. 52:2002;23-47
2. Perez C.A. Non-small cell carcinoma of the lung Dose-time parameters. Cancer Treat. Symp. 2:1985;131-142
3. Dillman R.O., Herndon J., Seagren S.L., et al. Improved survival in stage III non-small cell lung cancer Seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 Trial. J. Natl. Cancer Inst. 88:1996;1210-1215
4. Radiation Therapy Oncology Group. Eastern Cooperative Oncology Group, Komaki R., Scott C.B., Sause W.T., et al. Induction cisplatin/vinblastine and irradiation vs. irradiation in unresectable squamous cell lung cancer Failure patterns by cell type in RTOG 88-08/ECOG 4588. Int. J. Radiat. Oncol. Biol. Phys. 39:1997;537-544
5. Arriagada R., LeChevalier T., Rekacewicz C., et al. Cisplatin-based chemotherapy (CT) in patients with locally advanced non-small cell lung cancer (NSCLC) Late analysis of a French randomized trial program (abstract 1601). Proc. ASCO. 16:1997;446a
6. Arriagada R., LeChevalier T., Quoix E., et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in unresectable non-small Cell lung carcinoma. Lung Cancer. 10:(Suppl 1):1994;S239-244
7. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer A meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ. 311:1995;899-909
8. Furuse K., Fukuoka M., Kawahara M., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J. Clin. Oncol. 17:1999;2692-2699
9. Komaki R., Seiferheld W., Curran W., et al. Sequential vs. concurrent chemotherapy and radiation therapy for inoperable non-small cell lung cancer (NSCLC) Analysis of failures in a phase III study (RTOG 9410) (abstract). Int. J. Radiat. Oncol. Biol. Phys. 48:2000;113
10. Schild S.E., Stella P.J., Geyer S.M., et al. A phase III trial comparing chemotherapy plus either once a day radiotherapy (QD RT) or twice a day radiotherapy (BID RT) in stage III non-small cell lung cancer (NSCLC). Int. J. Radiat. Oncol. Biol. Phys. 54:2002;370-378
11. Arriagada R., LeChevalier T., Quoix E., et al. Effect of chemotherapy on locally advanced non-small cell lung carcinoma A randomized study of 353 patients. Int. J. Radiat. Oncol. Biol. Phys. 20:1991;1183-1190
12. Fletcher G.H. Clinical dose-response curves of human malignant epithelial tumours. Br. J. Radiol. 46:1973;1-12
13. Martel M.K., Ten Haken R.K., Hazuka M.B., et al. Estimation of tumor control probability model parameters from 3-D dose distributions of non-small cell lung cancer patients. Lung Cancer. 24:1999;31-37
14. Hayman J.A., Martel M.K., Ten Haken R.K., et al. Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy Update of a phase I study. J. Clin. Oncol. 19:2001;127-136
15. Rosenzweig K.E., Sim S.E., Mychalczak B., et al. Elective nodal irradiation in the treatment of non-small cell lung cancer with three-dimensional conformal radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 50:2001;681-685
16. Senan S., Burgers S., Samson M.J., et al. Can elective nodal irradiation be omitted in stage III non-small-cell lung cancer? Analysis of recurrences in a phase II study of induction chemotherapy and involved-field radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 54:2002;999-1006
17. International Commission on Radiation Units and Measurements, ICRU Report 50, section 2.4.8. Prescribing, Recording, and Reporting Photon Beam Therapy. 1993;ICRU, Bethesda
18. Emami B., Lyman J., Brown A., et al. Tolerance of normal tissue to therapeutic irradiation. Int. J. Radiat. Oncol. Biol. Phys. 21:1991;109-122
19. Armstrong J., Raben A., Zelefsky M., et al. Promising survival with three-dimensional conformal radiation therapy for non-small cell lung cancer. Radiother. Oncol. 44:1997;17-22
20. Graham M.V., Purdy J.A., Emami B., et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int. J. Radiat. Oncol. Biol. Phys. 45:1999;323-329
21. Maguire P.D., Marks L.B., Sibley G.S., et al. 73.6 Gy and beyond Hyperfractionated, accelerated radiotherapy for non-small-cell lung cancer. J. Clin. Oncol. 19:2001;705-711
22. Maguire P.D., Sibley G.S., Zhou S.M., et al. Clinical and dosimetric predictors of radiation-induced esophageal toxicity. Int. J. Radiat. Oncol. Biol. Phys. 45:1999;97-103